December 2, 2013
Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer
let us hope the best
These patients have no other hope at this time. So yes, lets hope CDX-011 extends their lives.
I wonder what it will do in combination with CDX-1127. Actually, many want to know.
Expect good things.
Their Phase II data must have been viewed positively by FDA in order to go for accelerated approval. They didn't launch this study on a whim; they had to have had signals from FDA.